Comparison of the second and third generation anti-cyclic citrullinated peptide antibody assays in the diagnosis of Japanese patients with rheumatoid arthritis

被引:0
作者
Kumi Shidara
Eisuke Inoue
Eiichi Tanaka
Daisuke Hoshi
Yohei Seto
Ayako Nakajima
Shigeki Momohara
Atsuo Taniguchi
Hisashi Yamanaka
机构
[1] Tokyo Women’s Medical University,Institute of Rheumatology
来源
Rheumatology International | 2011年 / 31卷
关键词
Anti-CCP antibody; Rheumatoid arthritis; Sensitivity; Specificity; Diagnosis;
D O I
暂无
中图分类号
学科分类号
摘要
The anti-cyclic citrullinated peptide (CCP) antibody has become increasingly important in the diagnosis of rheumatoid arthritis (RA), especially for early diagnosis. The purpose of this study is to compare the diagnostic usefulness of the second and third generation anti-CCP antibody kits among Japanese patients with RA. Anti-CCP antibody titers were measured with the second generation (MESACUP CCP test, Medical and biological laboratories) and third generation (QUANTA Lite CCP3 IgG ELISA, Inova Diagnostics) kits using serum samples from 106 rheumatoid arthritis (RA) patients and 57 non-RA patients. Sensitivities and specificities were compared. The sensitivity and specificity of the second generation anti-CCP (anti-CCP2) kit were 88.7 and 89.5%, and those of the third generation anti-CCP (anti-CCP3) kit were 91.5 and 87.7%. Area under the receiver operating curve showed that anti-CCP2 and anti-CCP3 had similar diagnostic performances. Diagnostic performance of the anti-CCP3 assay was comparable with the anti-CCP2 assay in Japanese patients with RA.
引用
收藏
页码:617 / 622
页数:5
相关论文
共 148 条
[1]  
Chen YF(2006)A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness Health Technol Assess 10 1-229
[2]  
Jobanputra P(2004)Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate Arthritis Rheum 50 1051-1065
[3]  
Barton P(2008)Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis Arthritis Rheum 59 1467-1474
[4]  
Jowett S(2008)Approaches to the treatment of early rheumatoid arthritis with disease-modifying antirheumatic drugs Br J Clin Pharmacol 66 173-178
[5]  
Bryan S(2009)Targeted ultrasound of the fifth metatarsophalangeal joint in an early inflammatory arthritis cohort Arthritis Rheum 61 1004-1008
[6]  
Clark W(2007)Comparison of second- and third-generation anti-cyclic citrullinated peptide antibodies assays for detecting rheumatoid arthritis Clin Chim Acta 386 76-81
[7]  
Maini RN(2008)Rheumatoid factor and anti-CCP autoantibodies in rheumatoid arthritis: a review Clin Lab Sci. 21 15-18
[8]  
Breedveld FC(2003)Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis Arthritis Rheum 48 2741-2749
[9]  
Kalden JR(2004)Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors Arthritis Rheum 50 380-386
[10]  
Smolen JS(2000)The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis Arthritis Rheum 43 1831-1835